IPP Bureau
Lonza scales bioconjugate innovation through enhanced synthesis offering
By IPP Bureau - February 21, 2026
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
FDA accepts Teva’s NDA for long-acting schizophrenia injection
By IPP Bureau - February 21, 2026
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill
By IPP Bureau - February 21, 2026
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients
By IPP Bureau - February 21, 2026
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer
By IPP Bureau - February 21, 2026
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria
By IPP Bureau - February 20, 2026
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research
By IPP Bureau - February 20, 2026
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer
By IPP Bureau - February 20, 2026
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Axol Bioscience acquires ophthalmology business from Newcells Biotech
By IPP Bureau - February 19, 2026
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences
By IPP Bureau - February 19, 2026
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
By IPP Bureau - February 19, 2026
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition
By IPP Bureau - February 19, 2026
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery
By IPP Bureau - February 19, 2026
Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients
By IPP Bureau - February 19, 2026
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
